From 1 August 2021, patients with unresectable or metastatic bowel cancer that is mismatch repair deficient (dMMR) will have a new treatment option, with the subsidised listing of Keytruda (Pembrolizumab) on the Pharmaceutical Benefits Scheme (PBS).

Tumours with the dMMR biomarker contain abnormalities that affect the proper repair of DNA inside the cell.

Play For Purpose is the ultimate not-for-profit raffle!
 
Every ticket gives you the chance to win awesome prizes, all while supporting Bowel Cancer Australia.
 
Raffle tickets are just $10, with a guaranteed minimum of $5 directly supporting the charity.
 

The latest National Bowel Cancer Screening Program (NBCSP) Report released today by the AIHW reveals participation rates continue to hover at 43.5% and colonoscopy wait times for those who receive a positive screen far exceed the recommended 30 days.

According to the report, 5.74 million people aged 50-74 were invited to participate in the NBCSP in 2018-19 but only 2.49 million took up the offer.
 

The biologic treatment Avastin has been withdrawn from the PBS as of today and a biosimilar brand called Mvasi has been listed.

Unless metastatic bowel cancer patients pay privately to continue treatment with Avastin, they will be force-switched to Mvasi.

A report written by Bowel Cancer Australia highlights the impact the COVID-19 pandemic has had on diagnosing Australia’s second deadliest cancer.
 
Colonoscopy waitlists existed prior to COVID-19 and have been further compounded further by the pandemic. Studies show delays increase the risk for bowel cancer progression and mortality.
 

The US Preventive Services Task Force (USPSTF) has recommended – for the first time - lowering the bowel cancer screening age from 50 to 45 for average-risk individuals.
 
We know this is a start, but there’s still a lot of work to be done.
 
Australia can’t afford to wait another 12 years for this country’s guidelines to be updated before taking action.
 

Approximately 5.74 million people aged 50-74 were invited to participate in the National Bowel Cancer Screening Program (NBCSP) between 1 January 2018 to 31 December 2019, according to data released today by the Australian Institute of Health and Welfare (AIHW).
 
Of those, only 2.49 million took up the offer to screen using the tax-funded kit delivered in the mail.
 
This was a participation rate of just 43.5%.
 

This year, My Giving Circle is giving $500,000 in grants to Australia’s favourite charities and not-for-profits voted by you.

Bowel Cancer Australia needs your vote to be in the running.

All you need to do is vote (for free) or donate to Bowel Cancer Australia through the My Giving Circle website.

A new report released today by social demographer Bernard Salt reveals a rising rate of bowel cancer among Generation Xers, notably from age 45. The report calls for the extension of the National Bowel Cancer Screening Program (NBCSP) to include people aged 45-74 (currently 50-74) to provide protection to an additional 2 million Australians, helping to reduce bowel cancer deaths.